- Home
- ZWS vs MIRM Comparison
ZWS vs MIRM Comparison
Compare ZWS & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZWS | MIRM |
|---|---|---|
| Founded | 1900 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 7.2B |
| IPO Year | 2008 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ZWS | MIRM |
|---|---|---|
| Price | $51.29 | $98.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $53.67 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.0M | 673.0K |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | 25.00 | ★ 74.59 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $1,530,500,000.00 | $19,138,000.00 |
| Revenue This Year | $6.90 | $26.22 |
| Revenue Next Year | $5.13 | $22.04 |
| P/E Ratio | $146.91 | ★ N/A |
| Revenue Growth | ★ 19.40 | N/A |
| 52 Week Low | $43.06 | $63.23 |
| 52 Week High | $55.00 | $130.00 |
Technical Indicators
Market Signals| Indicator | ZWS | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 58.04 | 37.39 |
| Support Level | $49.23 | $95.68 |
| Resistance Level | $51.65 | $107.51 |
| Average True Range (ATR) | 1.48 | 4.85 |
| MACD | 0.26 | -1.98 |
| Stochastic Oscillator | 55.07 | 32.91 |
Price Performance
Historical ComparisonAbout ZWS Zurn Elkay Water Solutions Corporation
Zurn Elkay Water Solutions Corp is a growth-oriented, pure-play water management business that designs, procures, manufactures, and markets the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. Its product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products, and filtered drinking water products for public and private spaces that deliver superior value to building owners, positively impact the environment and human hygiene and reduce product installation time.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.